Watch NUVB. Know when insiders buy.
One email the day a filing lands. Free.
Work order
40
WATCH · insiders 28, shorts 51
Insiders, 90 days
−$709K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
2 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.4BP/E —DIV YIELD —FCF YIELD —REV TTM $169.9M +1083.6%NET INCOME −$149.8MNET CASH $16M52W 3.01 – 9.54SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $31.7M | +555.6% | — | −$51M | −$62.8M | — | -0.18 | −$43M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | $83.2M | +2598.7% | — | $3.9M | $5.4M | — | 0.01 | $5.1M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | $41.9M | +633.1% | — | −$34M | −$36.6M | — | -0.11 | −$29.7M | $0 | −$29.7M | Mar 2 |
| Q3 2025 · Sep 30 | $13.1M | +1704.7% | 74.5% | −$56.4M | −$55.8M | — | -0.16 | −$52.9M | — | — | Nov 3 |
| Q2 2025 · Jun 30 | $4.8M | +236.8% | 46.7% | −$63.6M | −$59M | — | -0.17 | −$48.2M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | $3.1M | — | 32.1% | −$59M | −$53.2M | — | -0.16 | −$42.6M | — | — | Aug 6 |
| Q4 2024 · Dec 31derived | $5.7M | — | 26.2% | −$53.9M | −$49.4M | — | 0.00 | −$46.3M | $0 | −$46.3M | Mar 2 |
| Q3 2024 · Sep 30 | $727K | — | -108.4% | −$48.1M | −$41.2M | — | -0.15 | −$31.1M | — | — | Nov 3 |
| Q2 2024 · Jun 30 | $1.4M | — | 6.1% | −$470.4M | −$462.5M | — | -1.89 | −$37.3M | — | — | Nov 3 |
| Q1 2024 · Mar 31 | $0 | — | — | −$20.2M | −$14.8M | — | -0.07 | −$15.7M | — | — | Nov 3 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$20.8M | −$13.8M | — | -0.07 | −$15M | — | — | Mar 6 |
| Q3 2023 · Sep 30 | $0 | — | — | −$26.3M | −$19.6M | — | -0.09 | −$16.2M | — | — | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $62.9M | — | −$213.1M | −$204.6M | -325.3% | -0.60 | −$173.4M | $8M | −$181.4M | — | — |
| FY2024 · to Dec 31 | $7.9M | 10.1% | −$592.6M | −$567.9M | -7213.8% | -2.11 | −$130.4M | $0 | −$130.4M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$99.8M | −$75.8M | — | -0.35 | −$68M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$119.7M | −$104.2M | — | -0.48 | −$96.1M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$93.3M | −$86.8M | — | -0.44 | −$68.2M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$43.6M | −$41.7M | — | -0.43 | −$36.5M | — | — | — | — |
Every number comes from Nuvation Bio Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.